Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh
Fahima Chowdhury, Taufiqur Rahman Bhuiyan, Afroza Akter, Md Saruar Bhuiyan, Ashraful Islam Khan, Motaher Hossain, Imam Tauheed, Tasnuva Ahmed, Shaumik Islam, Tanzeem Ahmed Rafique, Shah Alam Siddique, Nabila Binta Harun, Khaleda Islam, John D Clemens, Firdausi Qadri, Fahima Chowdhury, Taufiqur Rahman Bhuiyan, Afroza Akter, Md Saruar Bhuiyan, Ashraful Islam Khan, Motaher Hossain, Imam Tauheed, Tasnuva Ahmed, Shaumik Islam, Tanzeem Ahmed Rafique, Shah Alam Siddique, Nabila Binta Harun, Khaleda Islam, John D Clemens, Firdausi Qadri
Abstract
After the large influx of Rohingya nationals (termed Forcibly Displaced Myanmar National; FDMN) from Rakhine State of Myanmar to Cox's Bazar in Bangladesh, it was apparent that outbreaks of cholera was very likely in this setting where people were living under adverse water and sanitation conditions. Large campaigns of oral cholera vaccine (OCV) were carried out as a preemptive measure to control cholera epidemics. The aim of the study was to evaluate the immune responses of healthy adults and children after administration of two doses of OCV at 14 days interval in FDMN population and compare with the response observed in Bangladeshi's vaccinated earlier. A cross-sectional immunogenicity study was conducted among FDMNs of three age cohort; in adults (18+years; n = 83), in older children (6-17 years; n = 63) and in younger children (1-5 years; n = 80). Capillary blood was collected at three time points to measure vibriocidal antibodies using either plasma or dried blood spot (DBS) specimens. There was a significant increase of responder frequency of vibriocidal antibody titer at day 14 in all groups for Vibrio cholerae O1 (Ogawa/Inaba: adults-64%/64%, older children-70%/89% and younger children-51%/75%). There was no overall difference of vibriocidal antibody titer between FDMN and Bangladeshi population at baseline (p = 0.07-0.08) and at day 14, day 28 in all age groups for both serotypes. The seroconversion rate and geometric mean titer (GMT) of either serotype were comparable using both plasma and DBS specimens. These results showed that OCV is capable of inducing robust immune responses in adults and children among the FDMN population which is comparable to that seen in Bangladeshi participants in different age groups or that reported from other cholera endemic countries. Our results also suggest that the displaced population were exposed to V. cholerae prior to seeking shelter in Bangladesh.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Mahmood SS, Wroe E, Fuller A, Leaning J. The Rohingya people of Myanmar: health, human rights, and identity. The Lancet. 2017;389(10081):1841–50.
- Beyrer C, Kamarulzaman A. Ethnic cleansing in Myanmar: the Rohingya crisis and human rights. The Lancet. 2017;390(10102):1570–3.
- ACTED, Faim AAMACL, International C, Aid C, NGOs CoD, Council DR, et al. One Year On: Meaningful progress needed to end impunity, discrimination and segregation in Rakhine State, say international agencies 2018 2018 [updated August 27; cited 2018 December 22]. Available from: .
- Pennington M. Bangladesh point finger at Myanmar for Rohingya 'genocide' 2018 [updated 27 September 2018; cited 2018 December 21]. Available from: .
- Summers A, Humphreys A, Leidman E, Van Mil LT, Wilkinson C, Narayan A, et al. Notes from the Field: Diarrhea and Acute Respiratory Infection, Oral Cholera Vaccination Coverage, and Care-Seeking Behaviors of Rohingya Refugees—Cox’s Bazar, Bangladesh, October–November 2017. Morbidity and Mortality Weekly Report. 2018;67(18):533 10.15585/mmwr.mm6718a6
- Aung WW, Okada K, Na-Ubol M, Natakuathung W, Sandar T, Oo NAT, et al. Cholera in Yangon, Myanmar, 2012–2013. Emerging Infectious Diseases. 2015;21(3):543 10.3201/eid2103.141309
- WHO. Global Health Observatory Myanmar statistics [cited 2018 October 31]. Available from: .
- WHO. Weekly epidemiological record 2016 [cited 2018 October 31]. 433–40]. Available from: .
- Review: Rohingya influx since 1978 2017 [cited 2018 December 22]. Available from: .
- Cousins S. Rohingya threatened by infectious diseases. The Lancet 2018;18(6):609–10. 10.1016/S1473-3099(18)30304-9
- Domman D, Chowdhury F, Khan AI, Dorman MJ, Mutreja A, Uddin MI, et al. Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. Nature genetics. 2018;50(7):951 10.1038/s41588-018-0150-8
- Islam MT, Khan AI, Sayeed MA, Amin J, Islam K, Alam N, et al. Field evaluation of a locally produced rapid diagnostic test for early detection of cholera in Bangladesh. PLoS neglected tropical diseases. 2019;13(1):e0007124 10.1371/journal.pntd.0007124
- Qadri F, Azad AK, Flora MS, Khan AI, Islam MT, Nair GB, et al. Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh. The Lancet. 2018;391(10133):1877–9.
- Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. New England Journal of Medicine. 2016;374(18):1723–32. 10.1056/NEJMoa1510330
- Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, Chowdhury F, et al. The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine. 2016;34(13):1551–8. 10.1016/j.vaccine.2016.02.020
- Qadri F, Mohi G, Hossain J, Azim T, Khan A, Salam M, et al. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol. 1995;2(6):685–8.
- Bhuiyan MS, Hossain M, Sharmin S, Shirin A, Khanam F, Chowdhury F, et al. Assessment of disease specific immune responses in enteric diseases using dried blood spot (DBS). PloS one. 2019;14(6):e0218353 10.1371/journal.pone.0218353
- Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011;29(46):8285–92. 10.1016/j.vaccine.2011.08.108
- Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, et al. Flexibility of oral cholera vaccine dosing—a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS neglected tropical diseases. 2015;9(3):e0003574 10.1371/journal.pntd.0003574
- Chowdhury F, Khan AI, Harris JB, LaRocque RC, Chowdhury MI, Ryan ET, et al. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. The Pediatric infectious disease journal. 2008;27(11):986 10.1097/INF.0b013e3181783adf
- Kanungo S, Lopez AL, Ali M, Manna B, Kim DR, Mahapatra T, et al. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. PloS one. 2014;9(5):e96499 10.1371/journal.pone.0096499
- Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, et al. Antigen-Specific Memory B-Cell Responses in Bangladeshi Adults after One- or Two-Dose Oral Killed Cholera Vaccination and Comparison with Responses in Patients with Naturally Acquired Cholera. Clinical and Vaccine Immunology. 2011;18(5):844–50. 10.1128/CVI.00562-10
- Akhtar M, Qadri F, Bhuiyan TR, Akter S, Rafique TA, Khan A, et al. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. Vaccine. 2017;35(2):321–8. 10.1016/j.vaccine.2016.11.055
- Desai SN, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim DR, et al. A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia. The American journal of tropical medicine and hygiene. 2015;93(3):527–33. 10.4269/ajtmh.14-0683
- Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, et al. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLoS neglected tropical diseases. 2014;8(5):e2828 10.1371/journal.pntd.0002828
- Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. The Journal of nutrition. 2001;131(5):1631S–6S. 10.1093/jn/131.5.1631S
- Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clinical Infectious Diseases. 2016;62(8):1043–8. 10.1093/cid/ciw001
Source: PubMed